In the US, IMMGOLIS® (ustekinumab-hmny) Injection is indicated for the treatment of adults patients with moderately to severely active rheumatoid arthritis in combination with methotrexate, and for the treatment of adult patients with moderately to severely active ulcerative colitis. The FDA also approved IMMGOLIS INTRI (golimumab-sldi), a biosimilar to Simponi Aria® (golimumab), for the treatment of adult patients with moderately to severely active RA in combination with methotrexate.
In the Europe, GOTENFIA® is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and ulcerative colitis
